Biomed Central Ltd

SHERPA: Unknown

People

  1. Budhu
    Budhu
  2. Hirschhorn Cymerman
    Hirschhorn Cymerman
  3. Liu
    Liu
  4. Mangarin
    Mangarin
  5. Gordon
    Gordon
  6. Janjigian
    Janjigian
  7. Kurtansky
    Kurtansky
  8. Markova
    Markova
  9. Moy
    Moy
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (7)
  2. Dermatology Service (7)
  3. Dermatology (7)
  4. Division of Subspecialty Medicine (7)
  5. Survivorship Research (7)
  6. Melanoma and Immunotherapeutics Service (4)
  7. Solid Tumor Oncology Division (4)
  8. Hematologic Malignancies, Division of (3)
  9. Sloan Kettering Institute Postdocs (3)
  10. GME, Medicine (2)
Search Within
  1. "Mario Lacouture"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
  3. Guidelines (1)
Groups
  1. Department of Medicine (7)
  2. Dermatology (7)
  3. Dermatology Service (7)
  4. Division of Subspecialty Medicine (7)
  5. Survivorship Research (7)
  6. Melanoma and Immunotherapeutics Service (4)

More Groups

People
  1. Mario Lacouture (7)
  2. Allison Betof Warner (2)
  3. Billel Gasmi (2)
  4. Cailian Liu (2)
  5. Czrina Cortez (2)
  6. Daniel Hirschhorn Cymerman (2)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2018 (1)
  4. 2017 (2)
  5. 2014 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (6)
  2. BMC Cancer (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of immune-related cutaneous adverse events with dupilumab
    Journal Article

    Kuo, A. M. S.; Gu, S.; Stoll, J.; Moy, A. P.; Dusza, S. W.; Gordon, A.; Haliasos, E. C.; Janjigian, Y.; Kraehenbuehl, L.; Quigley, E. A.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitors in patients with pre-existing psoriasis: Safety and efficacy
    Journal Article

    Halle, B. R.; Betof Warner, A.; Zaman, F. Y.; Haydon, A.; Bhave, P.; Dewan, A. K.; Ye, F.; Irlmeier, R.; Mehta, P.; Kurtansky, N. R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
    Guidelines

    Brahmer, J. R.; Abu-Sbeih, H.; Ascierto, P. A.; Brufsky, J.; Cappelli, L. C.; Cortazar, F. B.; Gerber, D. E.; Hamad, L.; Hansen, E.; Johnson, D. B.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn-Cymerman, D.; Ricca, J.; Gasmi, B.; De Henau, O.; Mangarin, L.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn, D.; Ricca, J.; Gasmi, B.; Mangarin, L. M.; De Henau, O.; Budhu, S.; Li, Y.; Cortez, C.; Xia, Y.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
    Journal Article

    Puzanov, I.; Diab, A.; Abdallah, K.; Bingham, C. O. 3rd; Brogdon, C.; Dadu, R.; Hamad, L.; Kim, S.; Lacouture, M. E.; LeBoeuf, N. R.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    Journal Article

    Maitland, M. L.; Levine, M. R.; Lacouture, M. E.; Wroblewski, K. E.; Chung, C. H.; Gordon, I. O.; Szeto, L.; Ratko, G.; Soltani, K.; Kozloff, M. F.; more...
    BMC Cancer (2014)

    Fulltext@MSK | Save